Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2014

View Archived Issues

Combination of GPR40 agonist and GLP-1 agonist improves glucose control in type 2 diabetes

WNT-974, a porcupine inhibitor targeting Wnt signaling in clinical testing

Candidate antidepressant mGlu2 and 3 receptor antagonists identified at Lilly

Development of a mouse model mimicking human ulcerative colitis

Paradigm to conduct genomic analysis to predict response to Tesaro's TSR-011

NuSirt Biopharma initiates phase II study of metformin/leucine combinations

Cardiac-selective sodium current inhibitor discovered at Gilead Sciences

ENSPIRIT trial of custirsen passes interim futility analysis

Heptares uses StaR platform to derive orexin receptor antagonists

Antitope and University College London to generate fully humanized antibodies

AbbVie begins phase I study of ABT-957 in subjects with Alzheimer's disease

Genentech begins phase I study of MOXR-0916 in locally advanced or metastatic solid tumors

Novel anti-HCV MAbs disclosed by Genentech

Researchers in Japan disclose humanized anti-HMGB1 MAbs

FDA grants Insys Therapeutics' cannabidiol orphan drug designation for GBM

Advaxis and Merck & Co. to collaborate on cancer immunotherapy combination trial

Nuvilex's cancer treatment evaluated in preclinical studies for malignant ascites

Enrollment open in phase I study of CB-5083 for relapsed/refractory multiple myeloma

Stanford University begins first-in-human study of Hu5F9-G4 for solid tumors

Vertex patents novel Na channel modulators

Naurex designs a new series of NMDA receptor modulators

DeuteRx divulges new deuterated PPAR-gamma agonists

Latuda launched in the U.K. for schizophrenia

Phase III REGULATE-PCI of Revolixys Kit halted

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...